© 2011

Drugs for HER-2-positive Breast Cancer

  • Maria Sibilia
  • Christoph C. Zielinski
  • Rupert Bartsch
  • Thomas W. Grunt

Part of the Milestones in Drug Therapy book series (MDT)

Table of contents

  1. Front Matter
    Pages i-ix
  2. Wolfgang J. Köstler, Yosef Yarden
    Pages 1-32
  3. Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello
    Pages 51-60
  4. Gunter von Minckwitz, Cristina Pirvulescu
    Pages 61-71
  5. Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer
    Pages 91-107
  6. Back Matter
    Pages 109-110

About this book


Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.


HER-2-positive Breast Cancer Pertuzumab Second Generation targeted Therapies Trastuzumab

Editors and affiliations

  • Maria Sibilia
    • 1
  • Christoph C. Zielinski
    • 2
  • Rupert Bartsch
    • 3
  • Thomas W. Grunt
    • 4
  1. 1.Medical University of Vienna, Department of Medicine IInstitute for Cancer ResearchViennaAustria
  2. 2.Medical University of Vienna, Department of Medicine IComprehensive Cancer CenterViennaAustria
  3. 3.Medical University of Vienna, Department of Medicine IComprehensive Cancer CentreViennaAustria
  4. 4.Medical University of Vienna, Department of Medicine IComprehensive Cancer CenterViennaAustria

Bibliographic information


From the reviews:

“This book takes readers on a journey from HER-2 signalling to therapeutic use of trastuzumab in the neoadjuvant, adjuvant and metastatic settings. … It is a tour-de-force and should be essential reading for anyone setting out in the HER-2 research field. … Overall, this small book covers the topic of HER-2 inhibition very well in a field that is rapidly changing.” (S. W. Wong and R. M. Lowenthal, Inflammation Research, Vol. 61, 2012)